Advertisement

The Acute Care of the Transplant Recipient

  • Phuong-Thu T. Pham
  • Phuong-Chi T. Pham
  • Gabriel M. Danovitch
Chapter

Abstract

Early post-transplant factors including delayed graft function (DGF), acute rejection episodes, nephrotoxic agents, post-transplant hypertension, dyslipidemia, and new onset diabetes mellitus after transplantation (NODAT) have all been implicated in worsening both short- and long-term morbidity and mortality after renal transplantation. Optimal management of the transplant recipient begins in the immediate postoperative period. This chapter provides a stepwise approach to the medical and urological management of the transplant recipient in the first 3 months after transplantation. The management of transplant recipients can be divided into three periods: immediate postoperative period, first week post-transplant, and first 3 months post-transplant. Immunosuppressive therapy is discussed in Chapter 9.

Keywords

Acute Rejection Renal Transplant Recipient Mycophenolate Mofetil Delay Graft Function Ureteral Obstruction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Shokes DA, Cecka JM. Effect of delayed graft function on short- and long-term kidney graft survival. In: Cecka JM and Terasaki PI (eds.), Clinical Transplants. UCLA Tissue typing Laboratory, Los Angeles, CA, 1997, pp. 297–303.Google Scholar
  2. 2.
    Lehtonen SRK, Isoniemi HM, Salmela KT et al. Long-term graft outcome is not necessarily affected by delayed onset of graft function and early acute rejection. Transplantation 1997;64:103–107.CrossRefPubMedGoogle Scholar
  3. 3.
    Paff WW, Howard RJ, Patton HP et al. Delayed graft function after renal transplantation. Transplantation 1998;65:219–223.Google Scholar
  4. 4.
    Ojo AO, Wolfe RA, Held WP et al. Delayed graft function: risk factors and implication for renal allograft survival. Transplantation 1997;63:968–974.CrossRefPubMedGoogle Scholar
  5. 5.
    Marcen R, Orofino L, Pascual J et al. Delayed graft function does not reduce the survival of renal transplant allografts. Transplantation 1998;66:461–466.CrossRefPubMedGoogle Scholar
  6. 6.
    Dawidson I et al. Perioperative albumin and verapamil improve early outcome after cadaveric renal transplantation. Transplant Proc 1994;26:3100–3101.PubMedGoogle Scholar
  7. 7.
    Gritsch HA, Rosenthal JM. The transplant operation and its surgical complications. In: GM Danovitch, (ed.), Handbook of Kidney Transplantation, 3rd ed. Lippincott, Williams and Wilkins, Philadelphia, PA, 2001, pp. 146–162.Google Scholar
  8. 8.
    Gritsch HA, Rosenthal JT, Danovitch GM. Living and cadaveric kidney donation. In Danovitch GM (ed.), Handbook of Kidney Transplantation. Little, Brown, Boston, 2001, pp. 111–129.Google Scholar
  9. 9.
    Fotiadas CN, Govani MV, Heldeman JH. Renal allograft dysfunction. In Massary SG, Galssock RJ (eds.), Textbook of Nephrology. Lippincott, Williams and Wilkins, Philadelphia, 2001, pp. 1617–1635.Google Scholar
  10. 10.
    Pham PT, Pham PC, Wilkinson AH. Management of the transplant recipient in the early postoperative period. In: Davison AM, Cameron JS, Grunfeld J-P, Ponticelli C, Ritz E, Winearls C, van Ypersele C (eds), Oxford Textbook Of Clinical Nephrology, 3rd ed. Oxford University Press, Oxford/New York, 2005, pp. 2087–2101.Google Scholar
  11. 11.
    Fernandez-Najera JE, Beltran S, Aparicio M et al. Transplant renal artery stenosis: association with vascular rejection. Transplant Proc 2006;38(8):2404–2405.CrossRefPubMedGoogle Scholar
  12. 12.
    Hawkins IF, Maynar M. Carbon dioxide digital subtraction angiography. In: Castadena Z (ed), Interventional Radiology, 3rd ed. Williams and Wilkins, Philadelphia, PA, 1997.Google Scholar
  13. 13.
    Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008;67(Suppl 3):66–69.CrossRefGoogle Scholar
  14. 14.
    Ploeg RJ, van Bockel JH, Langendijk PT et al. for the European Multicentre Study Group: Effect of preservation solution on results of cadaveric kidney transplantation. Lancet 1992;340:129–137.CrossRefPubMedGoogle Scholar
  15. 15.
    Yarlagadda SG, Klein CL, Jani A. Long-term renal outcomes after delayed graft function. Adv Chronic Kidney Dis 2008;15(3):248–256.CrossRefPubMedGoogle Scholar
  16. 16.
    Shokes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management, and long-term significance. J Urol 1996;155:1831-1840.CrossRefGoogle Scholar
  17. 17.
    Phillips AO, Deanne C, O’Donnell P et al. Evaluation of Doppler ultrasound in primary non-function of renal transplants. Clin Transplant 1994;8:83–86.PubMedGoogle Scholar
  18. 18.
    Pham PT, Peng A, Wilkinson AH et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000;36:844–850.CrossRefPubMedGoogle Scholar
  19. 19.
    Barone GW, Gurley BJ, Abul-Ezz SR et al. Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 2003;42:202–206.CrossRefPubMedGoogle Scholar
  20. 20.
    Baid S, Pascual M, Williams WW et al. Renal thrombotic microangiopathy associated with anti-cardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999;10:146–153.PubMedGoogle Scholar
  21. 21.
    Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 2006;6:2535–2542.CrossRefPubMedGoogle Scholar
  22. 22.
    Sharma M, Sharma R, Reddy SR et al. Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 2002;73(3):366–372.CrossRefPubMedGoogle Scholar
  23. 23.
    Watschinger B, Pascual M. Capillary C4d deposition as a marker of humoral immunity in renal allograft rejection. J Am Soc Nephrol 2002; 13:2420–2423.CrossRefPubMedGoogle Scholar
  24. 24.
    Mauiyyedi S, Covin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002;11:609–618.CrossRefPubMedGoogle Scholar
  25. 25.
    Solez K, Colvin RB, Racusen LC et al. Banff 2007 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8(4): 753–760.Google Scholar
  26. 26.
    Gaber AO et al. Results of double blind, randomized, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute allograft rejection episodes after renal transplantation. Transplantation 1998;96:29–37.CrossRefGoogle Scholar
  27. 27.
    Ibernon M, Gil-Vernet S, Carrera M et al. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation. Transplant Proc 2005;37(9):743–745.CrossRefGoogle Scholar
  28. 28.
    28. Jordan SC, Vo AA, Tyan D et al. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005;9(3):408–415.Google Scholar
  29. 29.
    Akalin E, Ames S, Sehgal V et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 2003;76(10):1444–1447.CrossRefPubMedGoogle Scholar
  30. 30.
    Berger PM, Diamond JR. Ureteral obstruction as complication of renal transplantation: a review. J Nephrol 1998;11:20–23.PubMedGoogle Scholar
  31. 31.
    Nargund VH, Cranston D. Urologic complications after renal transplantation. Transplant Rev 1996;10:24.CrossRefGoogle Scholar
  32. 32.
    Mylonakis E, Goes N, Rubin RH et al. BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation 2002;72:1587–1592.CrossRefGoogle Scholar
  33. 33.
    Singer J, Gritsch AH, Rosenthal JT. The transplant operation and its surgical complications. In: Danovitch GM (ed.), Handbook of Kidney Transplantation. Little, Brown, Boston, 2004, pp. 193–211.Google Scholar
  34. 34.
    Jaster R, Bittorf T, Klinken SP et al. Inhibition of proliferation but not erythroid differentiation of j2E cells by rapamycin. Biochem Pharmacol 1996;51:1181–1185.CrossRefPubMedGoogle Scholar
  35. 35.
    Augustine JJ, Rodriguez V, Padiyar A et al. Reduction of erythropoietin resistance after conversion from sirolimus to enteric coated mycophenolate sodium. Transplantation 2008;86(4):548–553.CrossRefPubMedGoogle Scholar
  36. 36.
    Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999;67:1036–1042.CrossRefPubMedGoogle Scholar
  37. 37.
    Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-1260.CrossRefPubMedGoogle Scholar
  38. 38.
    Luisa M et al. Thrombotic microangiopathy associated with parvovirus B19 infection after renal transplantation. J Am Soc Nephrol 2000;11:1132-1137.Google Scholar
  39. 39.
    Hartmann EL, Gatesman M, Roskopf-Somerville J et al. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant 2008;22(6):822–888.CrossRefPubMedGoogle Scholar
  40. 40.
    40. Vlahakos DV, Marathias KP, Agroyannis B et al. Posttransplant erythrocytosis. Kidney Int 2003;63(4):1187–1194.Google Scholar
  41. 41.
    Bacon BR, Rothman SA, Ricanati ES et al. Renal artery stenosis with erythrocytosis after renal transplantation. Arch Intern Med 1980;140:1206–.CrossRefPubMedGoogle Scholar
  42. 42.
    Wicker CG, Norman DJ, Bennison A et al. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int 1983;23:731–.CrossRefGoogle Scholar
  43. 43.
    Brox AG et al. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding protein. Transplantation 1998;66:1053–1058.CrossRefPubMedGoogle Scholar
  44. 44.
    Gupta M, Miller BA, Ahsan N et al. Expression of angiotensin II type 1 receptor on erythroid progenitors of patients with post transplant erythrocytosis. Transplantation 2000;70(8):1188–1194.CrossRefPubMedGoogle Scholar
  45. 45.
    Lezaic V et al. Erythrocytosis after kidney transplantation: the role of erythropoietin, burst promoting activity and early erythroid progenitor cells. Eur Med Res 2001;6:27–32.Google Scholar
  46. 46.
    Heering P, Degenhart S, Garbensee B. Tubular dysfunction following kidney transplantation. Nephron 1996;74:501–511.CrossRefPubMedGoogle Scholar
  47. 47.
    47. Pirenne J, Lledo-Garcia E, Benedetti E et al. Colon perforation after renal transplantation a single-institution review. Clin Transplant 1997; 11(2): 88–93.Google Scholar
  48. 48.
    48. Ward HN, Pabico RC, McKenna BA et al. The renal handling of phosphate by renal transplant recipients: correlation with serum parathyroid hormone, cyclic 35-adenosine monophosphate urinary excretion and allograft function. Adv Exp Med Biol 1997;81:173–181.Google Scholar
  49. 49.
    Kawarazaki H, Shibagaki Y, Shimizu H et al. Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia. Clin Exp Nephrol 2007;11(3):255–257.CrossRefPubMedGoogle Scholar
  50. 50.
    Ghanekar H, Welch BJ, Moe OW et al. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006;15(2):97–104.CrossRefPubMedGoogle Scholar
  51. 51.
    Levi M. Post transplant hypophosphatemia. Kidney Int 2001; 59:2377–2387.Google Scholar
  52. 52.
    Serra AL, Wuhmann C, Wuthrich RP. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis 2008;52(6):1151–1157.CrossRefPubMedGoogle Scholar
  53. 53.
    Borchhardt KA, Heinz H, Mayerwoger E et al. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008;86(7):919–924.CrossRefPubMedGoogle Scholar
  54. 54.
    Kruse AE, Eisenberger U, Frey FJ et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005;20(7):1311–1314.CrossRefPubMedGoogle Scholar
  55. 55.
    Bergua C, Torregrosa JV, Fuster D et al. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008;86(3):413–417.CrossRefPubMedGoogle Scholar
  56. 56.
    Pham PC, Pham PT:. Parathyroidectomy. In: Nissebson AR and Fine RN, (eds.), Handbook of Dialysis Therapy. Saunders, Elsevier, London, 2008, pp. 1024–1038.CrossRefGoogle Scholar
  57. 57.
    Barton CH. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med 1987;83:693–699.CrossRefPubMedGoogle Scholar
  58. 58.
    Gupta BK, Glicklich TVA. Magnesium repletion therapy improves lipid metabolism in hypomagnesemic renal transplant recipients. Transplantation 1999;67:1485-1487.CrossRefPubMedGoogle Scholar
  59. 59.
    Gane E, Pilmore H. Management of chronic hepatitis before and after renal transplantation. Transplantation 2002;74:427–437.CrossRefPubMedGoogle Scholar
  60. 60.
    Fabrizio F, Martin P. In: Danovitch GM(ed.). Handbook of Kidney Transplantation. Hepatitis in kidney Transplantation, 3rd ed. Lippincott Williams and Wilkins, Philadelphia, PA, 2001, pp. 263–271.Google Scholar
  61. 61.
    Fasola CG, Netto G, Christensen LL et al. Delay of hepatitis recurrence in liver transplant recipients treated with mycophenolate mofetil. Transplant Proc 2002;34:1561–1562.CrossRefPubMedGoogle Scholar
  62. 62.
    Bahra M, Neumann UIF, Jacob D et al. MMF and calcineurin inhibitor taper in recurrent hepatitis C after liver transplantation: Impact on histological course. Am J Transplant 2005;5:406–411.CrossRefPubMedGoogle Scholar
  63. 63.
    Nanmoku K, Imaizumi R, Tojimbra T et al. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy. Transplant Proc 2008;40(7):2382–2385.CrossRefPubMedGoogle Scholar
  64. 64.
    Amend WJ, Vincenti I, Tamlonovich SJ. The first two post-transplant months. In: Danovitch GM (ed.), Handbook of Kidney Transplantation. Little, Brown & Co, Boston, 2001, p. 167.Google Scholar
  65. 65.
    Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4(7): 1033–1041.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag US 2010

Authors and Affiliations

  • Phuong-Thu T. Pham
    • 1
  • Phuong-Chi T. Pham
    • 2
  • Gabriel M. Danovitch
    • 1
  1. 1.Division of Nephrology, Department of Medicine, Kidney and Pancreas Transplant ProgramDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.Division of Nephrology, Department of MedicineOlive View-UCLA Medical Center David Geffen School of Medicine at UCLASylmarUSA

Personalised recommendations